Literature DB >> 34615363

Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association.

Niteesh K Choudhry, Ian M Kronish, Wanpen Vongpatanasin, Keith C Ferdinand, Valory N Pavlik, Brent M Egan, Antoinette Schoenthaler, Nancy Houston Miller, David J Hyman.   

Abstract

The widespread treatment of hypertension and resultant improvement in blood pressure have been major contributors to the dramatic age-specific decline in heart disease and stroke. Despite this progress, a persistent gap remains between stated public health targets and achieved blood pressure control rates. Many factors may be important contributors to the gap between population hypertension control goals and currently observed control levels. Among them is the extent to which patients adhere to prescribed treatment. The goal of this scientific statement is to summarize the current state of knowledge of the contribution of medication nonadherence to the national prevalence of poor blood pressure control, methods for measuring medication adherence and their associated challenges, risk factors for antihypertensive medication nonadherence, and strategies for improving adherence to antihypertensive medications at both the individual and health system levels.

Entities:  

Keywords:  AHA Scientific Statements; hypertension; medication adherence

Mesh:

Substances:

Year:  2021        PMID: 34615363     DOI: 10.1161/HYP.0000000000000203

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Binge Drinking Among Adults with Hypertension in the USA, 2015-2020.

Authors:  Benjamin H Han; Stacy S Han; Joseph J Palamar
Journal:  J Gen Intern Med       Date:  2022-08-03       Impact factor: 6.473

2.  Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.

Authors:  Parisa Danaietash; Pierre Verweij; Ji-Guang Wang; George Dresser; Ilkka Kantola; Mary Katherine Lawrence; Krzysztof Narkiewicz; Markus Schlaich; Marc Bellet
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-06-09       Impact factor: 2.885

3.  Compliance with Lid Hygiene in Patients with Meibomian Gland Dysfunction.

Authors:  Varintorn Chuckpaiwong; Manachai Nonpassopon; Kaevalin Lekhanont; Weerapat Udomwong; Prae Phimpho; Nontawat Cheewaruangroj
Journal:  Clin Ophthalmol       Date:  2022-04-19

4.  Proceedings From a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension.

Authors:  Yvonne Commodore-Mensah; Fleetwood Loustalot; Cheryl Dennison Himmelfarb; Patrice Desvigne-Nickens; Vandana Sachdev; Kirsten Bibbins-Domingo; Steven B Clauser; Deborah J Cohen; Brent M Egan; A Mark Fendrick; Keith C Ferdinand; Cliff Goodman; Garth N Graham; Marc G Jaffe; Harlan M Krumholz; Phillip D Levy; Glen P Mays; Robert McNellis; Paul Muntner; Gbenga Ogedegbe; Richard V Milani; Linnea A Polgreen; Lonny Reisman; Eduardo J Sanchez; Laurence S Sperling; Hilary K Wall; Lori Whitten; Jackson T Wright; Janet S Wright; Lawrence J Fine
Journal:  Am J Hypertens       Date:  2022-03-08       Impact factor: 2.689

Review 5.  Rethinking Resistant Hypertension.

Authors:  Gabrielle Bourque; Swapnil Hiremath
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

6.  Length of initial prescription at hospital discharge and long-term medication adherence for elderly, post-myocardial infarction patients: a population-based interrupted time series study.

Authors:  J D Schwalm; Noah M Ivers; Zachary Bouck; Monica Taljaard; Madhu K Natarajan; Francis Nguyen; Waseem Hijazi; Kednapa Thavorn; Lisa Dolovich; Tara McCready; Erin O'Brien; Jeremy M Grimshaw
Journal:  BMC Med       Date:  2022-06-21       Impact factor: 11.150

Review 7.  A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider.

Authors:  Seyed Mehrdad Hamrahian; Omar H Maarouf; Tibor Fülöp
Journal:  Patient Prefer Adherence       Date:  2022-10-07       Impact factor: 2.314

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.